Skip to main content
Cancer Immunology, Immunotherapy : CII logoLink to Cancer Immunology, Immunotherapy : CII
. 1989 Jul;29(3):155–166. doi: 10.1007/BF00199990

Heterogeneous lymphokine-activated killer cell precursor populations

Development of a monoclonal antibody that separates two populations of precursors with distinct culture requirements and separate target-recognition repertoires

Bernard A Fox 1,, Steven A Rosenberg 1
PMCID: PMC11041048  PMID: 2786456

Abstract

We developed a monoclonal antibody (mAb) 211, which recognizes the precursors in peripheral blood of lymphokine-activated killer cells (LAK) induced by recombinant interleukin-2 (rIL-2). In conjunction with complement mAb 211 also eliminates natural killer cells (NK) and a majority of the cytotoxic T lymphocytes. B cells and monocytes do not express the 211 antigen. Since mAb 211 recognized such a large percentage of peripheral blood lymphocytes we examined which 211+ subpopulation was the predominant precursor of rIL-2-induced LAK cells using two-color fluoresence-activated cell sorting (fluorescein-conjugated 211 mAb plus phycoerythrin-CD11b). This method identified the 211+/ CD11b+ population as the predominant phenotype of the rIL-2-induced LAK precursor. In addition, we directly compared the phenotype of the LAK precursor induced by delectinated T-cell growth factor (TCGF) to that induced by rIL-2. The 211-depleted population, which was devoid of NK cells and LAK precursors (inducible by rIL-2), was capable of generating LAK activity when TCGF was used as the source of lymphokine. LAK cells induced by TCGF from the 211-depleted population lysed a fresh sarcoma and an NK-resistant cultured melanoma tumor target but not the Daudi cell line, which was lysed by rIL-2-induced LAK cells. Lymphoid subpopulations, depleted using NKH1a mAb, behaved similarly, generating high levels of lysis against the two solid tumor targets when cultured with TCGF but not with rIL-2. CD 3-depleted populations showed enrichment for LAK precursors using either rIL-2 or TCGF. These results indicate that while rIL-2-induced LAK precursors cannot be separated from cells with NK activity, TCGF-induced LAK cells can be generated from populations of peripheral blood mononuclear cells without NK activity.

Keywords: Natural Killer, Natural Killer Cell, Tumor Target, Natural Killer Activity, Daudi Cell

References

  • 1.Bevan MJ, Cohen M. Cytotoxic effects of antigen- and mitogen-induced T cells on various targets. J Immunol. 1975;114:559. [PubMed] [Google Scholar]
  • 2.Ferrini S, Miescher S, Zocchi MR, Fliedner VV, Moretta A. Phenotypic and functional characterization of recombinant interleukin 2 induced activated killer cells: analysis at the population and clonal levels. J Immunol. 1987;138:1297. [PubMed] [Google Scholar]
  • 3.Golub SH, Golightly MG, Zielske JV. “NK-like” cytotoxicity of human lymphocytes cultured in media containing fetal bovine serum. Int J Cancer. 1979;24:273. doi: 10.1002/ijc.2910240302. [DOI] [PubMed] [Google Scholar]
  • 4.Grimm EA, Rosenberg SA. Lymphokines, vol 9. Orlando, Fla: Academic Press; 1984. The human lymphokine-activated killer cell phenomenon; p. 279. [Google Scholar]
  • 5.Grimm EA, Mazumder A, Zhang HZ, Rosenberg SA. Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin-2-activated autologous human peripheral blood lymphocytes. J Exp Med. 1982;155:1823. doi: 10.1084/jem.155.6.1823. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Grimm EA, Ramsey KM, Mazumder A, Wilson DJ, Djeu JY, Rosenberg SA. Lymphokine-activated killer cell phenomenon. II. Precursor phenotype is serologically distinct from peripheral T lymphocytes, memory cytotoxic thymusderived lymphocytes, and natural killer cells. J Exp Med. 1983;157:884. doi: 10.1084/jem.157.3.884. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Itoh K, Tilden AB, Kumagai K, Balch CM. Leu 11 positive lymphocytes with natural killer activity are precursors of recombinant interleukin 2-induced activated killer cells. J Immunol. 1985;134:802. [PubMed] [Google Scholar]
  • 8.Itoh K, Tilden AB, Balch CM. Lysis of human solid tumor cells by lymphokine-activated natural killer cells. J Immunol. 1986;136:3910. [PubMed] [Google Scholar]
  • 9.Lanier LL, Benike CJ, Phillips JH, Engleman EG. Recombinant interleukin 2 enhanced natural killer cell-mediated cytotoxicity in human lymphocyte subpopulations expressing the Leu 7 and Leu 11 antigens. J Immunol. 1985;134:794. [PubMed] [Google Scholar]
  • 10.Reference deleted
  • 11.Lotze MT, Grimm EA, Mazumder A, Strausser JL, Rosenberg SA. Lysis of fresh and cultured autologous tumor by human lymphocytes cultured in T-cell growth factor. Cancer Res. 1981;41:4420. [PubMed] [Google Scholar]
  • 12.Mule JJ, Smith CA, Rosenberg SA. Interleukin 4 (B cell stimulatory factor 1) can mediate the induction of lymphokine-activated killer cell activity directed against fresh tumor cells. J Exp Med. 1987;166:792. doi: 10.1084/jem.166.3.792. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Mule JJ, Krosnick JA, Rosenberg SA. IL-4 regulation of murine lymphokine activated killer activity in vitro: effects on the IL-2-induced expansion, cytotoxicity, and phenotype of lymphokine-activated killer effectors. J Immunol. 1989;142:726. [PubMed] [Google Scholar]
  • 14.Muul LM, Rosenberg SA. New approaches to the immunotherapy of cancer based on the systemic administration of lymphokine-activated killer cells and recombinant interleukin 2. In: Cinader B, Miller RG, editors. Progress in immunology VI. Orlando, Fla: Academic Press; 1987. p. 714. [Google Scholar]
  • 15.Ortaldo JR, Mason A, Overton R. Lymphokine-activated killer cells. Analysis of progenitors and effectors. J Exp Med. 1986;164:1193. doi: 10.1084/jem.164.4.1193. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Owen-Schaub LB, Gutterman JU, Grimm EA. Synergy of tumor necrosis factor and interleukin 2 in the activation of human cytotoxic lymphocytes: Effect of tumor necrosis factor and interleukin 2 in the generation of human lymphokine-activated killer cell cytotoxicity. Cancer Res. 1988;48:788. [PubMed] [Google Scholar]
  • 17.Phillips JH, Lanier LL. Dissection of the lymphokine-activated killer phenomenon. Relative contribution of peripheral blood natural killer cells and T lymphocytes to cytolysis. J Exp Med. 1986;164:814. doi: 10.1084/jem.164.3.814. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Roberts K, Lotze MT, Rosenberg SA. The lymphokine activated killer cell. I. Separation and functional studies of the human precursor and effector cell. Cancer Res. 1987;47:4366. [PubMed] [Google Scholar]
  • 19.Rosenberg SA, Grimm EA, McGrogan M, Doyle M, Kawasaki E, Koths K, Mark DF. Biological activity of recombinant human interleukin-2 produced in Escherichia coli. . Science. 1984;223:1412. doi: 10.1126/science.6367046. [DOI] [PubMed] [Google Scholar]
  • 20.Rosenberg SA, Lotze MT, Muul LM, Chang AE, Avis FP, Leitman S, Linehan WM, Robertson CN, Lee RE, Rubin JT, Seipp CA, Simpson CG, White DE. A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high dose interleukin-2 alone. N Engl J Med. 1987;316:889. doi: 10.1056/NEJM198704093161501. [DOI] [PubMed] [Google Scholar]
  • 21.Rosenstein M, Yron I, Kaufman Y, Rosenberg SA. Lymphokine-activated killer cells: lysis of fresh syngeneic natural killer-resistant murine tumor cells by lymphocytes cultured in interleukin 2. Cancer Res. 1984;44:1946. [PubMed] [Google Scholar]
  • 22.Sharp TA, Gress RE, Sachs DH, Rosenberg SA. Assessment of mixed lymphocyte reactivity in human bone marrow cell cultures. Transplant. 1985;40:551. doi: 10.1097/00007890-198511000-00015. [DOI] [PubMed] [Google Scholar]
  • 23.Skibber J, Lotze MT, Uppenkamp I, Ross W, Rosenberg SA. Identification and expansion of human lymphokine-activated killer cells: implications for the immunotherapy of cancer. J Surg Res. 1987;42:613. doi: 10.1016/0022-4804(87)90004-7. [DOI] [PubMed] [Google Scholar]
  • 24.Springer TA. Monoclonal antibody analysis of complex biological systems. Combination of cell hybridization and immunoadsorbents in a novel cascade procedure and its application to the macrophage cells surface. J Biol Chem. 1981;256:3833. [PubMed] [Google Scholar]
  • 25.Tilden AB, Itoh K, Balch CM. Human lymphokine-activated killer (LAK) cells: identification of two types of effector cells. J Immunol. 1987;138:1068. [PubMed] [Google Scholar]
  • 26.Trinchieri G, Matsumoto-Kobayashi M, Clark SC, Seehra J, London L, Perussia B. Response of resting human peripheral blood natural killer cells to interleukin 2. J Exp Med. 1984;160:1147. doi: 10.1084/jem.160.4.1147. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Widmer MB, Acres RB, Sassenfeld HM, Grabstein KM. Regulation of cytolytic cell populations from human peripheral blood by B cell stimulatory factor 1 (interleukin 4) J Exp Med. 1987;166:1447. doi: 10.1084/jem.166.5.1447. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.Yang JC, Mule JJ, Rosenberg SA. Murine lymphokine-activated killer (LAK) cells; phenotypic characterization of the precursor and effector cells. J Immunol. 1986;137:715. [PubMed] [Google Scholar]
  • 29.Yron I, Wood TA, Jr, Spiess PJ, Rosenberg SA. In vitro growth of murine T cells V. The isolation and growth of lymphoid cells infiltrating syngeneic solid tumors. J Immunol. 1980;125:238. [PubMed] [Google Scholar]

Articles from Cancer Immunology, Immunotherapy : CII are provided here courtesy of Springer

RESOURCES